The research library
What the published work actually says
Every biologic Auvum works with, matched to the conditions it has been studied in, with a link to the source. Search by biologic, indication, disease or condition. We did not run these studies and we do not own them — they are other people's work, listed so you can read it yourself.
The life of the stem cell
From fertilization to year forty
A single cell at conception holds the entire organism. Over the decades that follow, developmental potency narrows. This is an explainer of that sequence — totipotency, pluripotency, the trophoblast lineage that hTSC lines come from, multipotency, and the adult stem-cell reservoirs that persist for life. It is not a protocol, not a treatment map, and not a claim that anything Auvum supplies is approved for human therapeutic use.
Methodology & data notes
Potency scores (0–100) are a qualitative index built for this visualisation, not a measured laboratory value. They rank developmental potential — totipotent (100) → pluripotent (~85) → multipotent (~50) → adult reservoir (~18) — so the decline can be read at a glance. They are not comparable across studies and should not be used as a specification.
Cell counts for embryonic stages are typical values from developmental-biology references; adult totals use the ~37 trillion figure from Bianconi et al. (2013). Individual variation is large.
Timeline spacing is deliberately non-linear. Days 0–12 weeks occupy roughly the first 45% of the rail and years 0–40 the remainder, so the embryonic stages stay legible. Read the rail as a sequence, not a scale.
Every stage links to its primary source. Where a claim is preclinical or in-vitro, the stage text says so. Nothing on this timeline should be read as a treatment claim: no hTSC- or exosome-derived product is FDA-approved for any indication.
Where our work concentrates
Working on something in this space?
If you are running a study, or thinking about one, we would rather talk to you early than late.
One example we follow: Life Biosciences’ ER-100, a partial epigenetic reprogramming therapy co-founded by Harvard geneticist Dr. David Sinclair, began first-in-human dosing for two eye conditions in early 2026. The trial is in its earliest phase, with no result yet to report.
ER-100 is a Life Biosciences programme, not Auvum’s. Auvum Bio is not affiliated with, sponsored by, or endorsed by Harvard University, Harvard Medical School, or Life Biosciences — we follow this trial because it matters to our field.